BridgeBio Pharma Inc
$ 76.75
-0.98%
17 Apr - close price
- Market Cap 15,026,311,000 USD
- Current Price $ 76.75
- High / Low $ 79.62 / 75.65
- Stock P/E N/A
- Book Value -10.71
- EPS -3.78
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -17.90 %
- 52 Week High 84.94
- 52 Week Low 31.77
About
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Analyst Target Price
$100.61
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-05 | 2025-04-30 | 2025-02-20 | 2024-11-01 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.9389 | -0.95 | -0.95 | -0.9888 | -1.3744 | -0.8596 | -0.39 | -0.2 | -0.96 | -1.08 | -0.98 | -0.92 |
| Estimated EPS | -0.716 | -0.88 | -0.75 | -0.89 | -1.09 | -0.98 | -1.06 | -0.71 | -0.91 | -0.82 | -0.83 | -0.83 |
| Surprise | -0.2229 | -0.07 | -0.2 | -0.0988 | -0.2844 | 0.1204 | 0.67 | 0.51 | -0.05 | -0.26 | -0.15 | -0.09 |
| Surprise Percentage | -31.1313% | -7.9545% | -26.6667% | -11.1011% | -26.0917% | 12.2857% | 63.2075% | 71.831% | -5.4945% | -31.7073% | -18.0723% | -10.8434% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.7 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BBIO
2026-04-16 20:39:03
Neil Kumar has reported beneficial ownership of 9,282,982 shares of BridgeBio Pharma (NASDAQ: BBIO), representing a 4.6% stake in the company. This ownership includes direct holdings, stock options exercisable within 60 days, restricted stock units (RSUs) vesting within 60 days, and shares held in family trusts. The SEC filing provides a detailed breakdown of his voting and dispositive powers over these shares.
2026-04-16 13:39:03
RBC Capital has initiated coverage on BridgeBio Pharma (BBIO) with an Outperform rating following the approval of its ATTR-CM treatment, Attruby. This new coverage highlights Attruby's commercial potential and BridgeBio's broader rare-disease pipeline, emphasizing the company's ability to translate scientific advancements into revenue. While Attruby's success and the pipeline's development, like BBP-418, are crucial for future growth, the company still faces challenges with net losses and potential future capital needs.
2026-04-16 01:39:03
Jefferies has reiterated a Buy rating and a $100 price target for BridgeBio Pharma (NASDAQ:BBIO), expecting Attruby sales to surpass consensus estimates in Q1 earnings. The company's stock has seen a 127% gain over the past year and analysts anticipate continued sales growth. BridgeBio's pipeline includes four oral drugs targeting rare diseases, with significant valuation support from new drug developments.
2026-04-15 23:10:12
Jefferies has reiterated a Buy rating and a $100 price target for BridgeBio Pharma (NASDAQ:BBIO), expecting Attruby sales to surpass consensus estimates and project over $9 billion in valuation support from three new rare disease drugs. The company is poised for significant growth with upcoming NDA submissions and forecasts to generate over $600 million in profits by 2028, despite not expecting profitability this year. Other analysts also maintain positive outlooks, citing strong performance and pipeline developments.
2026-04-14 13:10:12
BridgeBio Pharma CEO Neil Kumar sold 40,000 shares of the company's stock on April 9th for $2,984,800, part of a series of insider disposals totaling over $10 million. Despite these sales, the stock traded up 4.4% to $77.87, though the company remains unprofitable. Analysts currently rate BridgeBio Pharma as a "Moderate Buy" with a consensus target price of $87.38.
2026-04-14 03:38:48
An officer at BridgeBio Pharma (BBIO.US) sold 225,000 shares of common stock for a total value of $5.97 million. The transaction was executed at an average price of $26.51 per share. This sale indicates a significant executive divestment in the company's stock.
